M
Megan L. Troxell
Researcher at Stanford University
Publications - 148
Citations - 5098
Megan L. Troxell is an academic researcher from Stanford University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 35, co-authored 137 publications receiving 3908 citations. Previous affiliations of Megan L. Troxell include University of California, San Francisco & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
Frank B. Cortazar,Kristen A. Marrone,Megan L. Troxell,Kenneth M. Ralto,Melanie P. Hoenig,Julie R. Brahmer,Dung T. Le,Evan J. Lipson,Ilya G. Glezerman,Jedd D. Wolchok,Lynn D. Cornell,Paul Feldman,Michael B. Stokes,Sarah A. Zapata,F. Stephen Hodi,Patrick A. Ott,Michifumi Yamashita,David E. Leaf +17 more
TL;DR: CPI-induced AKI is a new entity that presents with clinical and histologic features similar to other causes of drug-induced acute tubulointerstitial nephritis, though with a longer latency period, and glucocorticoids appear to be a potentially effective treatment strategy.
Journal ArticleDOI
Identification of recurrent SMO and BRAF mutations in ameloblastomas
Robert T. Sweeney,Andrew C. McClary,Benjamin R. Myers,Jewison Biscocho,Lila Neahring,Kevin A. Kwei,Kunbin Qu,Xue Gong,Tony Ng,Carol D. Jones,Sushama Varma,Justin I. Odegaard,Toshihiro Sugiyama,Souichi Koyota,Brian P. Rubin,Megan L. Troxell,Robert J. Pelham,James L. Zehnder,Philip A. Beachy,Jonathan R. Pollack,Robert B. West +20 more
TL;DR: It is shown that a frequently occurring SMO alteration encoding p.Leu412Phe is an activating mutation and that its effect on Hedgehog-pathway activity can be inhibited by arsenic trioxide (ATO), an anti-leukemia drug approved by the US Food and Drug Administration that is currently in clinical trials for its Hedge Hog-inhibitory activity.
Journal ArticleDOI
Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients.
Juan Guo,Maria S. Tretiakova,Megan L. Troxell,Adeboye O. Osunkoya,Oluwole Fadare,Ankur R. Sangoi,Steven S. Shen,Antonio Lopez-Beltran,Rohit Mehra,Amer Heider,John P. Higgins,Lara Harik,Xavier Leroy,Anthony J. Gill,Kiril Trpkov,Steven C. Campbell,Christopher G. Przybycin,Christopher G. Przybycin,Cristina Magi-Galluzzi,Cristina Magi-Galluzzi,Jesse K. McKenney,Jesse K. McKenney +21 more
TL;DR: Tuberous sclerosis complex-associated RCCs have unique clinicopathologic features including female predominance, younger age at diagnosis, multiplicity, association with AMLs, 3 recurring histologic patterns, and an indolent clinical course.
Journal ArticleDOI
Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination
Katharina Röltgen,Sandra C. A. Nielsen,Oscar Silva,Sheren F. Younes,M. Zaslavsky,Cristina Costales,Fan Yang,Oliver F. Wirz,Daniel Solis,Ramona A. Hoh,A. Wang,Prabhu S. Arunachalam,Deana Colburg,Shu-hua Zhao,Emily Haraguchi,Alexandra S. Lee,Mihir Shah,Monali Manohar,Iris Chang,Fei Gao,Vamsee Mallajosyula,Chunfeng Li,James Liu,Massa J. Shoura,Sayantani B. Sindher,Elizabeth Parsons,Naranjargal Dashdorj,Naranbaatar Dashdorj,R W Monroe,Geidy E. Serrano,Thomas G. Beach,R. Sharon Chinthrajah,Gregory W. Charville,James L. Wilbur,Jacob N. Wohlstadter,Mark M. Davis,Bali Pulendran,Megan L. Troxell,George Sigal,Yasodha Natkunam,Benjamin A. Pinsky,Kari C. Nadeau,Scott D. Boyd +42 more
TL;DR: In this paper , the authors investigated whether antibodies stimulated by mRNA vaccination (BNT162b2), including third-dose boosting, differ from those generated by infection or adenoviral (ChAdOx1-S and Gam-COVID-Vac) or inactivated viral (BBIBP-CorV) vaccines.
Journal ArticleDOI
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology
Angela N. Bartley,Mary Kay Washington,Christina B. Ventura,Nofisat Ismaila,Carol Colasacco,Al B. Benson,Alfredo Carrato,Margaret L. Gulley,Dhanpat Jain,Sanjay Kakar,Helen Mackay,Catherine J. Streutker,Laura H. Tang,Megan L. Troxell,Jaffer A. Ajani +14 more
TL;DR: This guideline provides specific recommendations for assessment of HER2 in patients with advanced GEA while addressing pertinent technical issues and clinical implications of the results.